Work

A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors

Year: 2013

Type: article

Study design: Clinical Trial

Source: Investigational New Drugs

DOI: 10.1007/s10637-013-0044-7

Authors: Sharad Ghamande, Chia-Chi Lin, Daniel C. Cho, Geoffrey I. Shapiro, Eunice L. Kwak, Michael H. Silverman, Yunlong Tseng, Min-Wen Kuo, Wendy B. Mach, Shu-Chi Hsu, Teresa Coleman, James Chih-Hsin Yang, Ann-Lii Cheng, Mohammad H. Ghalib, Imran Chuadhary, Sanjay Goel

Institutions: Augusta University, National Taiwan University Hospital, Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute, Massachusetts General Hospital, Taiwan Liposome Company, Ltd. (Taiwan), Montefiore Medical Center, Albert Einstein College of Medicine

Language: English

Topic: Cancer therapeutics and mechanisms

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W1990642049

FWCI: 0.672

Cites: 9

Cited by: 25

Related to: 10